- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02513615
Epigenetic Determinants of Peritoneal Fibrosis
Study Overview
Status
Conditions
Detailed Description
There is considerable evidence that epigenetic changes in effector cells underlie the progressive nature of fibrogenic diseases. The investigators have developed an ex-vivo mesothelial cell culture system based on work by Aroeira and colleagues. Ex vivo cell cultures were treated with the DNA methyltransferase inhibitor 5-AZA for 72 hours. Overall, the investigators found that 11 of 14 patients' cells showed an increase in the E-Cad/alpha-SMA ratio with treatment to 5-AZA, indicating a return to a more epithelial-like phenotype and supporting an epigenetic mechanism of progressive fibrosis. The investigators hope to identify DNA methylation patterns associated with glucose exposure and peritoneal membrane solute transport in PD patients.
The investigators will take the peritoneal effluent from an overnight dwell from patients within one month of initiation of dialysis. The overnight effluent is centrifuged and the pellet is washed and cells are grown in DMEM medium. At confluence, cells are passaged into 2 flasks then taken for DNA and RNA. At 12 months, a second overnight peritoneal effluent sample will be obtained. The investigators will also gather demographic data (patient's age, diabetes, occurrence of peritonitis, cumulative PD prescription including total glucose exposure, use of icodextrin, and the results of a peritoneal equilibrium test carried out for clinical purposes between 3 and 12 months from the start of peritoneal dialysis). The investigators will use whole genome DNA methylation analysis to assess epigenetic changes in mesothelial cells from incident PD patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with end stage renal disease recently started on peritoneal dialysis. Patients will be over the age of 18.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNA methylation pattern
Time Frame: 12 months
|
DNA methylation pattern will be measured after 12 months of glucose exposure compared with a baseline sample.
Gene expression will be measured by Genome wide methylation analysis.
In the incident patients, a within-subject analysis will be carried out between the naive and 12 month cell culture sample.
Gene expression analysis will be performed with the statistical software R and "BioConductor", a collection of tools for gene expression analysis.
Gene-level summaries from Human HT-12 BeadChip data will be generated using the widely used Bioconductor package lumi, which includes background correction, variance stabilization and normalization of expression data.
The Linear Models for Microarray Analysis (LIMMA) package of Bioconductor will be used for differential expression analysis.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNA methylation and solute transport
Time Frame: 12 months
|
The investigators will correlate changes in DNA methylation with solute transport measured by a peritoneal equilibrium test and peritoneal glucose exposure.
Solute transport is calculated from the dialysate to plasma creatinine ratio which is obtained from the peritoneal equilibrium test.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter J Margetts, MD PhD, McMaster University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14CECPDNA1006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Fibrosis
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingPeritoneal SclerosisChina
-
National Taiwan University HospitalUnknownPeritoneal FibrosisTaiwan
-
Pius-Hospital OldenburgUniversity of Leipzig; University of OldenburgUnknown
-
Instituto Nacional de Cardiologia Ignacio ChavezCompletedEnd Stage Renal DiseaseMexico
-
Radboud University Medical CenterOnze Lieve Vrouwe GasthuisTerminatedPostoperative Adhesion | Peritoneal Adhesion, NosNetherlands
-
Weill Medical College of Cornell UniversityUnknownCirrhosis | Spontaneous Bacterial PeritonitisUnited States
-
Centre Hospitalier Universitaire, AmiensTerminated
-
Tanta UniversityUnknown
-
University of PadovaTerminatedCirrhosis | Ascites | Nosocomial Spontaneous Bacterial PeritonitisItaly
-
Assiut UniversityCompletedSpontaneous Bacterial PeritonitisEgypt